INL 4
Alternative Names: INL-4Latest Information Update: 28 Jun 2023
At a glance
- Originator Innolife
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Atherosclerosis in China
- 27 May 2019 Preclinical trials in Atherosclerosis in China (unspecified route) (Innolife pipeline, May 2019)